ACT 7-IMMUNE RESPONSE & OUTCOME OF SEQUENTIAL FLAVIVIRUS INFECTIONS MOUSE MODEL
ACT 7-IMMUNE RESPONSE & OUTCOME OF SEQUENTIAL FLAVIVIRUS INFECTIONS MOUSE MODEL
批准号:
7715302
负责人:
IDALI MARTINEZ-MARTINEZ
金额:
$11.95万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-08-01 至 2009-07-31
关键词:
Active ImmunizationAnimalsAntigensBiological AssayBirdsBloodBrainClinicalComputer Retrieval of Information on Scientific Projects DatabaseCountryDNA VaccinesDengueDengue VirusEncephalitisEquus caballusFeverFlavivirus InfectionsFundingFutureGrantHumanImmuneImmune responseIndirect Fluorescent Antibody TechniqueIndividualInfectionInstitutionKineticsMeasuresMonitorMonkeysMorbidity - disease rateMouse StrainsMusNeutralization TestsOutcomePassive ImmunizationPlayPredispositionRangeReportingResearchResearch PersonnelResourcesRoleSerumSourceSouth AmericaSymptomsSystemTestingUnited StatesUnited States National Institutes of HealthVaccinesViral Load resultViral ProteinsVirusVirus DiseasesWest IndiesWest Nile viruscross reactivitycytokinedaydesignepizooticimprovedmortalitymouse modelpathogenresearch studytransmission process
中文摘要
这个子项目是许多研究子项目中利用
资源由NIH/NCRR资助的中心拨款提供。子项目和
调查员(PI)可能从NIH的另一个来源获得了主要资金,
并因此可以在其他清晰的条目中表示。列出的机构是
该中心不一定是调查人员的机构。
西尼罗河病毒(West Nile,WNV)是一种新出现的病毒,于1999年引入美国,并在全国迅速传播。这种病毒在过去两年中导致了12000多例报告的人类病例,其临床症状从轻微的发烧疾病到潜在的致命脑炎。对西尼罗河病毒在中南美洲和加勒比海岛屿等登革热流行地区的传播知之甚少。流行病研究表明,该病毒正在马、鸟和可能的人类中传播,但这些国家尚未报告有症状的WN病例。由于DEN和WNV抗原之间存在广泛的交叉反应,我们的假设是,对登革热病毒(DENV)免疫的个体可能对WNV疾病具有交叉保护作用。为了证明这一假设,我们将使用Balb/c小鼠进行动物研究。我们将首先评估WNV在该小鼠株中感染的敏感性和动力学(特定目标1)。然后,将进行两个单独的实验,以测试是否可以通过DENV或DEN-2候选DNA疫苗的主动免疫(特定目标2)或从初次或继发性DENV感染中收集的人血清被动免疫(特定目标3)来实现对西尼罗河病毒的交叉保护。对DENV和WNV的免疫反应将通过间接免疫荧光试验、中和试验和使用Bio-plex系统的细胞因子分析来测量。西尼罗河病毒攻击后的小鼠发病率和死亡率将被监测28天,血液和脑中的病毒载量将通过Taqman分析来确定。如果实现了交叉保护,这些实验将使我们能够确定可能与保护相关的免疫反应的类型和持续时间。未来的研究将致力于确定可能在交叉保护中发挥重要作用的DEN病毒蛋白。这项研究和未来对猴子的研究结果将为改进广谱疫苗的设计提供有价值的信息,这种疫苗可能对DENV和WNV这两种病原体具有潜在的保护作用。
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
West Nile (WNV) is an emerging virus that was introduced in the United States on 1999 and has expanded rapidly throughout the country. This virus caused more than 12,000 reported human cases in the last two years with clinical symptoms that ranged from a mild febrile illness to a potentially fatal encephalitis. Little is known about WNV transmission in dengue-endemic regions, such as Central and South America and the Caribbean islands. Epizootic studies demonstrated that the virus is circulating in horses, birds and probably humans but symptomatic WN cases have not yet been reported in these countries. Since there is extensive cross reactivity between DEN and WNV antigens, our hypothesis is that individuals that are immune to dengue viruses (DENV) may be cross-protected against WNV illnesses. To prove this hypothesis, we will perform animal studies using Balb/c mice. We will first evaluate the susceptibility and kinetics of WNV infection in this mice strain (specific aim 1). Then, two separate experiments will be performed to test if cross-protection against WNV can be achieved by active immunization with DENV or a DEN-2 DNA vaccine candidate (specific aim 2) or passive immunization with human serum collected from primary or secondary DENV infections (specific aim 3). Immune responses against DENV and WNV will be measured by indirect immunofluorescence assays, neutralization tests and cytokine assays using the Bio-plex system. Mice morbidity and mortality after WNV challenge will be monitored for 28 days and viral loads in blood and brain will be determined by Taqman assays. If cross-protection is achieved, these experiments will allow us to determine the type and duration of the immune responses that may correlate with protection. Future studies will be aimed to determine the DEN viral proteins that may play an important role in cross-protection. Results from this and future studies in monkeys will provide valuable information to improve the design of broad spectrum vaccines that could potentially protect against both pathogens, DENV and WNV.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ACT 7-IMMUNE RESPONSE & OUTCOME OF SEQUENTIAL FLAVIVIRUS INFECTIONS MOUSE MODEL
-
批准号:8357166
-
项目类别:
-
资助金额:$10.6万
-
财政年份:2011
-
负责人:IDALI MARTINEZ-MARTINEZ
-
依托单位:
ACT 7-IMMUNE RESPONSE & OUTCOME OF SEQUENTIAL FLAVIVIRUS INFECTIONS MOUSE MODEL
-
批准号:8166220
-
项目类别:
-
资助金额:$10.18万
-
财政年份:2010
-
负责人:IDALI MARTINEZ-MARTINEZ
-
依托单位:
ACT 7-IMMUNE RESPONSE & OUTCOME OF SEQUENTIAL FLAVIVIRUS INFECTIONS MOUSE MODEL
-
批准号:7959199
-
项目类别:
-
资助金额:$14.65万
-
财政年份:2009
-
负责人:IDALI MARTINEZ-MARTINEZ
-
依托单位:
ACT 7-IMMUNE RESPONSE & OUTCOME OF SEQUENTIAL FLAVIVIRUS INFECTIONS MOUSE MODEL
-
批准号:7561543
-
项目类别:
-
资助金额:$12.46万
-
财政年份:2007
-
负责人:IDALI MARTINEZ-MARTINEZ
-
依托单位:
BIOMARKERS FOR EARLY DIAGNOSIS OF DENGUE
-
批准号:7011613
-
项目类别:
-
资助金额:$1.85万
-
财政年份:2004
-
负责人:IDALI MARTINEZ-MARTINEZ
-
依托单位:
Evaluation Studies of a Dengue-2 DNA Vaccine in Monkeys
-
批准号:6671170
-
项目类别:
-
资助金额:$29.8万
-
财政年份:2003
-
负责人:IDALI MARTINEZ-MARTINEZ
-
依托单位:
Evaluation Studies of a Dengue-2 DNA Vaccine in Monkeys
-
批准号:6779943
-
项目类别:
-
资助金额:$26.08万
-
财政年份:2003
-
负责人:IDALI MARTINEZ-MARTINEZ
-
依托单位:
EVALUATION OF DENGUE 2 ENVELOPE DNA BASED VACCINE
-
批准号:6660082
-
项目类别:
-
资助金额:$23.08万
-
财政年份:2002
-
负责人:IDALI MARTINEZ-MARTINEZ
-
依托单位:
EVALUATION OF DENGUE 2 ENVELOPE DNA BASED VACCINE
-
批准号:6644304
-
项目类别:
-
资助金额:$23.08万
-
财政年份:2002
-
负责人:IDALI MARTINEZ-MARTINEZ
-
依托单位:
EVALUATION OF DENGUE 2 ENVELOPE DNA BASED VACCINE
-
批准号:6504114
-
项目类别:
-
资助金额:$23.08万
-
财政年份:2001
-
负责人:IDALI MARTINEZ-MARTINEZ
-
依托单位:
MINORITY PREDOCTORAL FELLOWSHIP PROGRAM--NIGMS
-
批准号:2208556
-
项目类别:
-
资助金额:$1.33万
-
财政年份:1995
-
负责人:IDALI MARTINEZ-MARTINEZ
-
依托单位:
海外基金